Literature DB >> 6223730

Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activity.

C F Scott, L E Spitler.   

Abstract

Lymphocytotoxic activity has been found by previous investigators in multiple sclerosis (MS) sera. We confirmed the presence of this activity in MS sera using techniques designed to eliminate possible sources of erroneous conclusion not considered in previous studies. We further characterized this activity and found it to be non-dialysable and complement dependent, and, therefore, presumably to be an antibody. This lymphocytotoxic antibody (LCA) is found in those patients with active or progressive disease, and appears to be preferentially directed against the suppressor subset of T cells, as defined by monoclonal antibodies. The LCA may play a role in the pathogenesis of acute exacerbation of MS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223730      PMCID: PMC1535529     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Lymphocytotoxic antibodies in multiple sclerosis.

Authors:  A L Schocket; H L Weiner; J Walker; K McIntosh; P F Kohler
Journal:  Clin Immunol Immunopathol       Date:  1977-01

Review 2.  Significance of virus antibodies in multiple sclerosis.

Authors:  M Haire
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

Review 3.  Multiple sclerosis: an immunologic reassessment.

Authors:  P Y Paterson
Journal:  J Chronic Dis       Date:  1973-03

4.  Cytotoxins in disease. Autocytotoxins in lupus.

Authors:  P I Terasaki; V D Mottironi; E V Barnett
Journal:  N Engl J Med       Date:  1970-10-01       Impact factor: 91.245

Review 5.  Laboratory diagnosis of multiple sclerosis: immunological and biochemical aspects.

Authors:  E J Thompson
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

6.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

7.  Leukocyte iso- and autoantibodies in multiple sclerosis (MS) with special regard to complement-dependent cold-reacting auto-lymphocytotoxins (CoCoCy).

Authors:  E Kuwert; J Bertrams
Journal:  Eur Neurol       Date:  1972       Impact factor: 1.710

8.  Nature of cold-reactive antibodies to lymphocyte surface determinants in systemic lupus erythematosus.

Authors:  J B Winfield; R J Winchester; P Wernet; S M Fu; H G Kunkel
Journal:  Arthritis Rheum       Date:  1975 Jan-Feb

9.  Multiple sclerosis: immunologic aspects.

Authors:  R P Lisak
Journal:  Ann Clin Lab Sci       Date:  1975 Sep-Oct       Impact factor: 1.256

10.  Histocompatibility (HL-A) antigens and lymphocytotoxic antibodies in systemic lupus erythematosus (SLE).

Authors:  K M Nies; J C Brown; E L Dubois; F P Quismorio; G J Friou; P I Terasaki
Journal:  Arthritis Rheum       Date:  1974 Jul-Aug
View more
  6 in total

Review 1.  Immunoregulatory T cells in multiple sclerosis: markers and functions.

Authors:  M A Bach
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Takahisa Masaki; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-01-02       Impact factor: 3.478

3.  Peripheral blood lymphocyte phenotype and function in multiple sclerosis.

Authors:  P J Hughes; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

4.  Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients.

Authors:  H Ohguro; S Chiba; Y Igarashi; H Matsumoto; T Akino; K Palczewski
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  Normal T cell subsets and lymphocyte activity in multiple sclerosis.

Authors:  M M Albala; D Davignon; L D Fast; D D Clark
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

Review 6.  Abnormalities of serum and plasma components in patients with multiple sclerosis.

Authors:  H C Ford
Journal:  Clin Biochem       Date:  1985-02       Impact factor: 3.281

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.